Indolent lymphomas (iNHL) form an heterogenous group accounings for 1/3 of all malignant lymphomas with Follicular lymphoma (FL) being the most common subtype. iNHL are characterized by repeated relapses. Among available treatment lines, autologous (auto) and allogeneic (allo) HCT are the only curative options for relapsed disease. Nevertheless, the roles of both forms of HCT are evolving and are currently being challenged as T-cell engaging therapies emerge. The indications for auto-HCT and allo-HCT in 2023 are reviewed in this chapter.
Copyright 2024, The Author(s).